Black Diamond Therapeutics

OverviewSuggest Edit

Black Diamond Therapeutics is a biotechnology company. It is focused on the development of selective medicines for patients with genetically-defined cancers driven by oncogenes activated by allosteric mutations.

TypePublic
Founded2017
HQCambridge, US
Websiteblackdiamondtherapeutics.com

Latest Updates

Employees (est.) (Jan 2020)31(+4%)
Job Openings14
Revenue (FY, 2019)$0
Share Price (Oct 2020)$32.8
Cybersecurity ratingAMore

Key People/Management at Black Diamond Therapeutics

David M. Epstein

David M. Epstein

Co-Founder, President & Chief Executive Officer and Director
Ali Behbahani

Ali Behbahani

Director
Elizabeth Buck

Elizabeth Buck

Co-Founder, Executive Vice President, Discovery & Translational Sciences
Brad Bolzon

Brad Bolzon

Director
Brent Hatzis-Schoch

Brent Hatzis-Schoch

Chief Operating Officer, General Counsel
Christopher Roberts

Christopher Roberts

Chief Scientific Officer
Show more

Black Diamond Therapeutics Office Locations

Black Diamond Therapeutics has offices in Cambridge, New York, Stony Brook and Toronto
Cambridge, US (HQ)
139 Main St #301
New York, US
180 Varick St 6th floor
Stony Brook, US
25 Health Sciences Drive
Toronto, CA
661 University Ave
Show all (4)

Black Diamond Therapeutics Financials and Metrics

Black Diamond Therapeutics Revenue

USD

Net income (Q2, 2020)

(14.6m)

EBIT (Q2, 2020)

(15.0m)

Market capitalization (15-Oct-2020)

1.2b

Closing stock price (15-Oct-2020)

32.8

Cash (30-Jun-2020)

64.0m

EV

1.1b
Black Diamond Therapeutics's current market capitalization is $1.2 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

General and administrative expense

6.7m2.0m7.6m

R&D expense

3.5m7.0m21.8m

Operating expense total

4.1m8.9m29.3m
Quarterly
USDQ1, 2020Q2, 2020

General and administrative expense

5.5m4.9m

R&D expense

7.4m10.2m

Operating expense total

12.9m15.0m

EBIT

(12.9m)(15.0m)
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

7.9m51.7m154.7m

Prepaid Expenses

36.0k24.0k1.0m

Current Assets

7.9m51.7m155.7m

PP&E

102.0k134.0k164.0k
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020

Cash

78.7m357.2m64.0m

Prepaid Expenses

294.0k4.9m3.8m

Current Assets

79.0m362.1m208.2m

PP&E

116.0k154.0k166.0k
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(4.6m)(8.9m)(35.3m)

Depreciation and Amortization

24.0k44.0k47.0k

Accounts Payable

(59.0k)264.0k1.5m

Cash From Operating Activities

(2.4m)(8.5m)(24.7m)
Quarterly
USDQ3, 2018Q3, 2019Q1, 2020Q2, 2020

Net Income

(5.9m)(25.4m)(12.1m)(26.7m)

Depreciation and Amortization

32.0k38.0k10.0k23.0k

Accounts Payable

337.0k496.0k2.4m(1.4m)

Cash From Operating Activities

(6.1m)(17.2m)(11.3m)(24.9m)
USDFY, 2017

Financial Leverage

-1.2 x
Show all financial metrics

Black Diamond Therapeutics Operating Metrics

Jan, 2020

Patent Applications

7
Show all operating metrics

Black Diamond Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Black Diamond Therapeutics (Canada) Inc
Black Diamond Therapeutics Security Corporation

Black Diamond Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Black Diamond Therapeutics Online and Social Media Presence

Embed Graph

Black Diamond Therapeutics News and Updates

Black Diamond Therapeutics to Present Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium

CAMBRIDGE, Mass. and NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that pre-clinical data on the Company’s lead…

Black Diamond Therapeutics Announces the Appointment of Biopharmaceutical Veteran Robert A. Ingram as Chairman of the Board

CAMBRIDGE, Mass. and NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Robert A. Ingram as the …

Black Diamond Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass. and NEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today reported financial results for the second quarter ende…

Black Diamond Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass. and NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Offic…

Black Diamond Therapeutics Announces the Appointment of Fang Ni as Chief Business Officer

CAMBRIDGE, Mass. and NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Fang Ni, Pharm.D., as Chi…

Black Diamond Therapeutics Granted Fast Track Designation by the FDA for BDTX-189 for the Treatment of Adult Patients with a Solid Tumor Harboring an Allosteric HER2 Mutation or an EGFR or HER2 Exon 20 Insertion Mutation

CAMBRIDGE, Mass. and NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that the U.S. Food and Drug Administration (…
Show more

Black Diamond Therapeutics Blogs

Black Diamond Therapeutics Frequently Asked Questions

  • When was Black Diamond Therapeutics founded?

    Black Diamond Therapeutics was founded in 2017.

  • Who are Black Diamond Therapeutics key executives?

    Black Diamond Therapeutics's key executives are David M. Epstein, Ali Behbahani and Elizabeth Buck.

  • How many employees does Black Diamond Therapeutics have?

    Black Diamond Therapeutics has 31 employees.

  • Who are Black Diamond Therapeutics competitors?

    Competitors of Black Diamond Therapeutics include Moleculin Biotech, Verastem and Karyopharm Therapeutics.

  • Where is Black Diamond Therapeutics headquarters?

    Black Diamond Therapeutics headquarters is located at 139 Main St #301, Cambridge.

  • Where are Black Diamond Therapeutics offices?

    Black Diamond Therapeutics has offices in Cambridge, New York, Stony Brook and Toronto.

  • How many offices does Black Diamond Therapeutics have?

    Black Diamond Therapeutics has 4 offices.